GRAL Grail (GRAL) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-medical laboratories · CIK 0001699031
Form 144 · 6
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
189
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $370.3K priced
What the filings say about GRAL
Insiders, 180 days
-$14.9M net sold
3 sellers · 86% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$12.8M
6 notices
Grail insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, GRAIL, Inc. insiders sold a net $14.9M of stock across 81 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 21, 2026.
- The trade is 0.1% of the 361,871 shares held after it.
- 2 other insiders sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ofman Joshua J. sold about $53.2K of GRAL under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 21, 2026.
- The trade is 0.3% of the 360,871 shares held after it.
- 2 other insiders sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ofman Joshua J. sold about $134.4K of GRAL under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 21, 2026.
- The trade is 1.0% of the 357,471 shares held after it.
- 2 other insiders sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ofman Joshua J. sold about $460.5K of GRAL under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 21, 2026.
- The trade is 2.0% of the 350,419 shares held after it.
- 2 other insiders sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ofman Joshua J. sold about $964.9K of GRAL under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.Context
- 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Sep 21, 2026.
- The trade is 1.8% of the 344,385 shares held after it.
- 2 other insiders sold within 30 days.
- 189 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Ofman Joshua J. sold about $830.5K of GRAL under a 10b5-1 plan on Oct 15, 2026; 2 other insiders sold within 30 days and 189 funds added in the latest 13F quarter.81 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$14.9M over 180 days
-$14.8M over 90 days
below 76% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
189 funds bought in last quarter
more than 76% of Healthcare Services
Revenue
+17.2% year over year
more than 64% of Healthcare Services
Margin
-277.5% net margin
below 97% of Healthcare Services
Buybacks
no share repurchases reported
Short interest
23.3% of the float short (float per yahoo 2026-10-26) · 4.1 days to cover · settled 2026-09-30
more than 94% of Healthcare Services
What changed in the last 30 days
Oct 16Chief Executive Officer Ofman Joshua J. sold $2.7M under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 7Chief Financial Officer Freidin Aaron sold $3.5M (Oct 5)
Oct 7Chief Growth Officer Partridge Andrew John sold $1.2M (Oct 5)
Oct 5Officer Aaron Freidin filed to sell $3.5M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 5Officer Andrew Partridge filed to sell $1.2M by Oct 5 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch GRAL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+66.2%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GRAL: institutional holders (13F)
13F holdings, latest reported quarter
4,161,584 sh
$284.1M
4,028,614 sh
$275.0M
3,577,075 sh
$244.2M
3,102,891 sh
$211.8M
2,385,514 sh
$162.9M
Congress trades in GRAL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GRAL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
JOSHUA OFMAN
Filed 2026-10-15
$698.5K
Aaron Freidin
Filed 2026-10-05
$3.5M
Andrew Partridge
Filed 2026-10-05
$1.2M
JOSHUA OFMAN
Filed 2026-09-21
$5.8M
AARON FREIDIN
Filed 2026-08-27
$955.1K
GRAL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Inception Portfolio
$9.0M position · as of 2026-06-30
3.2%
Clough Select Equity ETF
$1.3M position · as of 2026-07-31
2.6%
SLOW CAPITAL GROWTH FUND
$2.5M position · as of 2026-07-31
2.3%
EQ/Morgan Stanley Small Cap Growth Portfolio
$8.4M position · as of 2026-06-30
1.8%
ROBO Global Healthcare Technology and Innovation ETF
$1.2M position · as of 2026-07-31
1.7%
PRIMECAP Odyssey Aggressive Growth Fund
$108.3M position · as of 2026-07-31
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Grail, Inc. Pac
Cycle 2026 · $159K spent
$146.0K
Federal Election Commission, matched by the PAC's connected organisation
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $14.9M sold by insiders over 180 days, 189 funds added last quarter, $12.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
GRAL financials
Revenue growth
+17.2%
XBRL, annual
Net margin
-277.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$165.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM GRAL
| FY Dec 2025 | $147.2M |
| FY Dec 2024 | $125.6M |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | $44.7M |
| Mar 2026 | $40.8M |
| Dec 2025 | $43.6M |
| Sep 2025 | $36.2M |
| Jun 2025 | $35.5M |
| Mar 2025 | $31.8M |
| Dec 2024 | $38.3M |
| Sep 2024 | $28.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-236.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM GRAL
| FY Dec 2025 | -277.5% |
| FY Dec 2024 | -1,614% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -246.7% |
| Mar 2026 | -228.5% |
| Dec 2025 | -227.5% |
| Sep 2025 | -245.8% |
| Jun 2025 | -320.7% |
| Mar 2025 | -333.6% |
| Dec 2024 | -253.8% |
| Sep 2024 | -438.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$296.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM GRAL
| FY Dec 2025 | -$299.9M |
| FY Dec 2024 | -$582.4M |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -$81.2M |
| Mar 2026 | -$87.5M |
| Dec 2025 | -$63.9M |
| Sep 2025 | -$63.6M |
| Jun 2025 | -$77.3M |
| Mar 2025 | -$95.1M |
| Dec 2024 | -$93.8M |
| Sep 2024 | -$105.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-16.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GRAL
| FY Dec 2025 | -16.1% |
| FY Dec 2024 | -81.0% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -16.1% |
| Mar 2026 | -16.1% |
| Dec 2025 | -16.1% |
| Sep 2025 | -16.8% |
| Jun 2025 | -17.7% |
| Mar 2025 | -79.3% |
| Dec 2024 | -81.0% |
| Sep 2024 | -81.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GRAL
| FY Dec 2025 | -13.8% |
| FY Dec 2024 | -58.8% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -14.1% |
| Mar 2026 | -14.0% |
| Dec 2025 | -13.8% |
| Sep 2025 | -14.2% |
| Jun 2025 | -14.8% |
| Mar 2025 | -67.2% |
| Dec 2024 | -58.8% |
| Sep 2024 | -67.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-20.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GRAL
| FY Dec 2025 | -19.6% |
| FY Dec 2024 | -65.8% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -20.7% |
| Mar 2026 | -19.8% |
| Dec 2025 | -19.6% |
| Sep 2025 | -20.7% |
| Jun 2025 | -21.8% |
| Mar 2025 | -76.3% |
| Dec 2024 | -65.8% |
| Sep 2024 | -74.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-5.0%
TTM free cash flow over market value at close 2026-10-23
FCF yield GRAL
| FY Dec 2025 | -9.0% |
| FY Dec 2024 | -97.1% |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | -10.1% |
| Mar 2026 | -13.8% |
| Dec 2025 | -9.0% |
| Sep 2025 | -15.5% |
| Jun 2025 | -20.1% |
| Mar 2025 | -54.0% |
| Dec 2024 | -97.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GRAL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Jan 2023 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2023-01 | |
|---|---|---|---|---|
| Revenue | $147.2M | $125.6M | $93.1M | $55.5M |
| Operating income | -$562.2M | -$2.2B | -$1.5B | -$5.4B |
| Net income | -$408.4M | -$2.0B | -$1.5B | -$5.4B |
| EPS (diluted) | -11.11 | -63.54 | -47.21 | -173.89 |
| Operating cash flow | -$299.0M | -$577.2M | -$595.8M | -$561.3M |
| Cash | $249.7M | $214.2M | $97.3M | $241.6M |
SEC XBRL, fiscal years, as known on 2026-10-27
GRAL Stock Sonar score 5/7 axes
Find similar shapesCompareGRAL ranks highest on institutional and government (78th percentile) and growth (64th), and lowest on risk and compliance (16th), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GRAL filings, in plain words
Are Grail insiders buying or selling GRAL?
In the 180 days to 2026-10-27, Grail insiders were net sellers, a net $14.9M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of GRAL?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $12.8M of stock; the latest, by JOSHUA OFMAN, was filed 2026-10-15.
Read the full summary
In the 180 days to 2026-10-27, Grail insiders were net sellers of GRAL, a net $14.9M across purchases and sales reported on Form 4 by 3 sellers. 86% of the 22 insider sales were made under a pre-arranged Rule 10b5-1 plan, so most selling was scheduled in advance. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $12.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
